Centre de messages

Actualités

Avutometinib and Defactinib Show Significant Activity in LGSOC

An international phase II study led by Verastem demonstrates that the combination of avutometinib and defactinib has a significant effect on response rate, duration of response, and progression-free…

Actualités

New Study Confirms Beneficial Effect of Relacorilant

An international phase III study conducted by Corcept demonstrates that the combination of relacorilant and nab-paclitaxel results in a statistically significant improvement in progression-free…

Actualités

Pembrolizumab Improves Disease-Free Survival in dMMR Endometrial Carcinoma

A randomized double-blind phase III study conducted by Merck Sharp & Dohme demonstrates that adding pembrolizumab to first-line chemotherapy does not improve disease-free survival in the overall…

Actualités

New treatment successfull in therapy resistant ovarian cancer

An international trial, led by UZ Leuven, shows that ovarian cancer patients treated with an antibody combined with chemotherapy have a longer survival compared to patients treated with standard…

Actualités

Immunotherapy Combined with Chemotherapy Improves PFS in Endometrial Carcinoma

An international phase III study led by AstraZeneca demonstrates that adding durvalumab to standard chemotherapy followed by maintenance therapy with durvalumab, with or without olaparib,…

Actualités

Tisotumab Vedotin Represents a Promising Treatment Approach in Cervical Cancer

An international phase Ib/II study led by Genmab demonstrates that tisotumab vedotin combined with bevacizumab, pembrolizumab, or carboplatin shows promising activity in cervical cancer. The study…

Actualités

Genetic test determines maintenance treatment for ovarian cancer

Researchers in Leuven develop a genetic test to determine in which patients a maintenance treatment with PARP inhibitors would be effective

Actualités

Therapy resistance in ovarian cancer unraveled

Ovarian cancer can usually be treated effectively with platin-based treatments, but over time nearly all patients do relapse because the tumour cells become resistant. A preclinical trial led by UZ…